AFM
MDGL icon

Anson Funds Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Anson Funds Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-28,263
Closed -$348K – 73
2015
Q4 		$348K Buy
+28,263
New +$776K 0.11% 51

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Anson Funds Management's MDGL Position: Q1 2016 in Review

Anson Funds Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2016, closing a stake of 28,263 shares — an estimated $348K sold.

Anson Funds Management first reported a position in MDGL in Q4 2015 and held it in 1 quarter. The position peaked at $348K in Q4 2015. 68 funds tracked by Wall St. Rank hold MDGL as of Q1 2016.

  • Anson Funds Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Anson Funds Management sold 28,263 Madrigal Pharmaceuticals shares in Q1 2016, an estimated $348K.
  • Anson Funds Management first reported a position in Madrigal Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Anson Funds Management's Madrigal Pharmaceuticals position peaked at $348K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2016.

Based on Anson Funds Management's 13F filing for Q1 2016, filed 13 May 2016.